IGF1R and neoplasm: The circulating IGF-1 levels are closely associated with the risk of cancer [8, 9], and the blockade of IGF-1R, using anti-IGF-R1 antibodies, IGF1R antisense, and inhibitory analogues of IGF-1 suppress tumor cell growth and angiogenesis [10-13].